Skip to main content

Table 3 Incidence of adverse effects by drugs

From: Is switching intravesical chemotherapeutic agents beneficial in short-term recurrent high-risk non-muscle-invasive bladder tumors? A 5-year retrospective study

Symptom

EPI(n = 83)

GEM(n = 81)

HCPT(n = 41)

 

Grade I–II

Grade I–II

Grade I–II

P value

Dysuria (n%)

5(6.0)

4(4.9)

2(4.9)

 

Frequency (n%)

8 (9.6)

7(8.6)

4(9.8)

 

Urgency (n%)

7(8.4)

6 (7.4)

3(7.3)

 

Hematuria (n%)

14(16.9)

8 (9.9)

4(9.8)

 

Fever (n%)

3(3.6)

2(2.5)

1(2.4)

 

Chemical cystitis (n%)

2(2.4)

1(1.2)

1(2.4)

 

Nausea and gvomitin (n%)

1(1.2)

0 (0)

0(0)

 

Total (n%)

40(48.2)

28(34.6)

15(36.6)

0.175

  1. EPI epirubicin, GEM gemcitabine, HCPT hydroxycamptothecin